As it transitions from a pure platform play to a product company, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continues to do deals for its RNAi technology as well as partnerships for its development programs. The biotech has done at least eight deals since January 2011, when it announced its 5x15 program to focus on its internal pipeline. Since inception, Alnylam has done at least 37 deals for its RNAi technology and products